# Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

> **NCT07459296** · PHASE3 · RECRUITING · sponsor: **First Affiliated Hospital of Guangxi Medical University** · enrollment: 266 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma (NPC)

## Interventions

- **DRUG:** Becotatug Vedotin
- **DRUG:** Sintilimab
- **DRUG:** Cisplatin
- **RADIATION:** intensity-modulated radiotherapy
- **DRUG:** Gemcitabine (GEM)
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT07459296
- **Lead sponsor:** First Affiliated Hospital of Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2030-04-01
- **Final completion:** 2032-04-01
- **Target enrollment:** 266 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07459296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07459296, "Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07459296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*